Recent Development of Nanomaterials for Transdermal Drug Delivery

Leong, Moong Yan; Kong, Yeo Lee; Burgess, Kevin; Wong, Won Fen; Sethi, Gautam; Looi, Chung Yeng

doi:10.3390/biomedicines11041124

Cited by 23 publications

(5 citation statements)

References 256 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, larger nanoparticles (size > 200 nm) encounter difficulty in penetrating the skin barrier and delivering the carried drug into the bloodstream, with the primary challenge lying in the ineffective permeation through the stratum corneum barrier. 93 , 94 Moreover, in non-nano carrier systems, surfactants cause a greater lipid disorientation effect in the stratum corneum and result in higher levels of cutaneous absorption compared to terpenes and solvents. 95 Increasing the concentration ratio of the surfactant in the nano carrier composition may not always lead to enhanced permeability of the carrier; conversely, it could impede the release of the drug or carrier due to interfacial interactions.…”

Section: Resultsmentioning

confidence: 99%

Key Transdermal Patch Using Cannabidiol-Loaded Nanocarriers with Better Pharmacokinetics in vivo

Chu,

Liao,

Liu

et al. 2024

IJN

View full text Add to dashboard Cite

Purpose: Cannabidiol (CBD) is a promising therapeutic drug with low addictive potential and a favorable safety profile. However, CBD did face certain challenges, including poor solubility in water and low oral bioavailability. To harness the potential of CBD by combining it with a transdermal drug delivery system (TDDS). This innovative approach sought to develop a transdermal patch dosage form with micellar vesicular nanocarriers to enhance the bioavailability of CBD, leading to improved therapeutic outcomes. Methods: A skin-penetrating micellar vesicular nanocarriers, prepared using nano emulsion method, cannabidiol loaded transdermal nanocarriers-12 (CTD-12) was presented with a small particle size, high encapsulation efficiency, and a drug-loaded ratio for CBD. The skin permeation ability used Strat-M™ membrane with a transdermal diffusion system to evaluate the CTD and patch of CTD-12 (PCTD-12) within 24 hrs. PCTD-12 was used in a preliminary pharmacokinetic study in rats to demonstrate the potential of the developed transdermal nanocarrier drug patch for future applications. Results: In the transdermal application of CTD-12, the relative bioavailability of the formulation was 3.68 ± 0.17-fold greater than in the free CBD application. Moreover, PCTD-12 indicated 2.46 ± 0.18-fold higher relative bioavailability comparing with free CBD patch in the ex vivo evaluation. Most importantly, in the pharmacokinetics of PCTD-12, the relative bioavailability of PCTD-12 was 9.47 ± 0.88-fold higher than in the oral application. Conclusion: CTD-12, a transdermal nanocarrier, represents a promising approach for CBD delivery, suggesting its potential as an effective transdermal dosage form.

show abstract

Section: Resultsmentioning

confidence: 99%

Key Transdermal Patch Using Cannabidiol-Loaded Nanocarriers with Better Pharmacokinetics in vivo

Chu,

Liao,

Liu

et al. 2024

IJN

View full text Add to dashboard Cite

show abstract

“…Nonetheless, CANPs still improved the skin retention of PH compared to the solution. This could be attributed to several properties associated with CANPs, including particle size, enhanced adhesion, controlled release, and protection from external factors [ 44 , 84 ]. These combined mechanisms contributed to the superior skin retention observed with PH-loaded CANPs, especially F4.…”

Section: Resultsmentioning

confidence: 99%

Chitosan Alginate Nanoparticles of Protein Hydrolysate from Acheta domesticus with Enhanced Stability for Skin Delivery

Yeerong,

Chantawannakul,

Anuchapreeda

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

This study aimed to develop chitosan alginate nanoparticles (CANPs) for enhanced stability for dermal delivery of protein hydrolysate from Acheta domesticus (PH). CANPs, developed using ionotropic pre-gelation followed by the polyelectrolyte complex technique, were characterized for particle size, polydispersity index (PDI), and zeta potential. After the incorporation of PH into CANPs, a comprehensive assessment included encapsulation efficiency, loading capacity, morphology, chemical analyses, physical and chemical stability, irritation potential, release profile, skin permeation, and skin retention. The most optimal CANPs, comprising 0.6 mg/mL sodium alginate, 1.8 mg/mL calcium chloride, and 0.1 mg/mL chitosan, exhibited the smallest particle size (309 ± 0 nm), the narrowest PDI (0.39 ± 0.01), and pronounced negative zeta potential (−26.0 ± 0.9 mV), along with an encapsulation efficiency of 56 ± 2%, loading capacity of 2.4 ± 0.1%, release of 40 ± 2% after 48 h, and the highest skin retention of 12 ± 1%. The CANPs induced no irritation and effectively enhanced the stability of PH from 44 ± 5% of PH remaining in a solution to 74 ± 4% after three-month storage. Therefore, the findings revealed the considerable potential of CANPs in improving PH stability and skin delivery, with promising applications in cosmetics and related fields.

show abstract

“…Nanotechnology has revolutionized transdermal drug administration by providing novel strategies to overcome the skin’s natural barrier characteristics (Rabiei et al., 2020 ). Nano-sized drug carriers, such as liposomes, niosomes, and micelles, are designed to carry drugs through the skin’s outermost layer, the stratum corneum, which is a key challenge in transdermal delivery (Alkilani et al., 2015 ; Leong et al., 2023 ). For example, niosomes are self-assembled vesicles made of nonionic surfactants and cholesterol that have the potential to be used as drug delivery carriers.…”

Section: Transdermal Enhancement Technologiesmentioning

confidence: 99%

Breaking boundaries: the advancements in transdermal delivery of antibiotics

Zaid Alkilani,

Hamed,

Musleh

et al. 2024

Drug Delivery

View full text Add to dashboard Cite

Transdermal drug delivery systems (TDDS) for antibiotics have seen significant advances in recent years that aimed to improve the efficacy and safety of these drugs. TDDS offer many advantages over other conventional delivery systems such as non-invasiveness, controlled-release pattern, avoidance of first-pass metabolism. The objective of this review is to provide an overview on the recent advances in the TDDS of different groups of antibiotics including β-lactams, tetracyclines, macrolides, and lincosamides, utilized for their effective delivery through the skin and to explore the challenges associated with this field. The majority of antibiotics do not have favorable properties for passive transdermal delivery. Thus, novel strategies have been employed to improve the delivery of antibiotics through the skin, such as the use of nanotechnology (nanoparticles, solid-lipid nanoparticles, nanoemulsions, vesicular carriers, and liposomes) or the physical enhancement techniques like microneedles and ultrasound. In conclusion, the transdermal delivery systems could be a promising method for delivering antibiotics that have the potential to improve patient outcomes and enhance the efficacy of drugs. Further research and development are still needed to explore the potential of delivering more antibiotic drugs by using various transdermal drug delivery approaches.

show abstract

Recent Development of Nanomaterials for Transdermal Drug Delivery

Cited by 23 publications

References 256 publications

Key Transdermal Patch Using Cannabidiol-Loaded Nanocarriers with Better Pharmacokinetics in vivo

Key Transdermal Patch Using Cannabidiol-Loaded Nanocarriers with Better Pharmacokinetics in vivo

Chitosan Alginate Nanoparticles of Protein Hydrolysate from Acheta domesticus with Enhanced Stability for Skin Delivery

Breaking boundaries: the advancements in transdermal delivery of antibiotics

Contact Info

Product

Resources

About